Bropirimine as neoadjuvant therapy decreases residual disease and expression of markers PCNA and TGF-beta 1 in a rat orthotopic prostate adenocarcinoma.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples